Department of Surgery, University of British Columbia, Canada.
Semin Immunol. 2011 Aug;23(4):304-13. doi: 10.1016/j.smim.2011.04.001. Epub 2011 May 28.
Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured.
降低慢性排斥反应的发生率和减少对终身免疫抑制的需求仍然是临床移植中的重要目标。在本文中，我们将回顾调节性 T 细胞（Treg）如何被认为是一种预防或治疗同种异体移植排斥反应的有吸引力的方法，Treg 可以在体内被操纵或扩增的方式，以及体外扩增/产生的 Treg 用于细胞治疗的潜力。我们将描述已经或正在临床中进行的第一个调节性 T 细胞治疗，以及这些治疗的安全性问题和如何衡量结果。
